UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000016256
Receipt number R000018781
Scientific Title A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)
Date of disclosure of the study information 2015/01/19
Last modified on 2020/09/06 16:02:07

No. Disposal Last modified on Item of update
1 Insert 2015/01/18 23:05:39
2 Update 2015/06/09 23:53:08 Recruitment status
3 Update 2015/06/10 01:01:44 Email
4 Update 2016/07/22 19:49:48 Name of primary person or sponsor
Organization
5 Update 2017/01/30 22:08:39 Last follow-up date
6 Update 2017/07/27 06:43:11 Institutions
7 Update 2018/05/01 00:02:26 Email
8 Update 2018/05/10 20:37:57 Email
9 Update 2018/08/01 07:10:53 UMIN ID1
10 Update 2018/08/01 07:26:24 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Institute
11 Update 2018/08/08 19:16:23 Organization
Organization
Division name
Division name
Address
Address
TEL
Organization
Organization
Division name
Division name
Address
Address
TEL
12 Update 2018/10/04 22:49:05 Recruitment status
13 Update 2018/10/04 22:59:38 Last follow-up date
14 Update 2019/01/23 21:48:12 Anticipated trial start date
15 Update 2019/07/24 19:26:05 Number of participants that the trial has enrolled
16 Update 2020/01/05 21:17:12 Date of IRB
Date analysis concluded
17 Update 2020/09/06 15:48:29 Recruitment status
18 Update 2020/09/06 16:02:07 Results Delayed
Results Delay Reason
Results Delay Reason